Related Experiment Video
Updated: Jan 11, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Evaluating the impact of decentralized testing for tuberculosis in Ghana: A simulation model
Parastu Kasaie1, Lad Dombrowski2, Jeffrey Pennington1
1Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, United States of America.
None:
Poor geographical accessibility to tuberculosis (TB) diagnostic services in Ghana is a key barrier to timely diagnosis. Decentralizing molecular testing for TB could improve TB case notification among underserved populations and enhance treatment initiation while avoiding unnecessary treatments. This study aims to project the epidemiological impact of decentralized TB testing at the country level. We developed an individual-based simulation of the TB diagnostic system and treatment cascade in Ghana, calibrated to key TB care targets using data from the District Health Information Management System (DHIMSII) from 2019-2022. We assessed the effects of expanding molecular (Xpert MTB/RIF) testing to (1) all 218 district hospitals and (2) all 703 modeled facilities reporting TB notifications, comparing these scenarios to the current diagnostic network. Under the baseline scenario, 26% of samples remained untested, with over 30% of diagnoses made through clinical judgment alone, and 35% with false positive diagnoses. Decentralizing Xpert to district-level facilities could reduce the proportion of untested samples to 20%, lowering false positive diagnosis to 32%. While projected TB notifications and treatment rates in 2030 remained similar, this shift could result in 51 additional treatment initiations for individuals with undiagnosed TB, prevent 36 unnecessary treatments, and save 43 lives per million people over an eight-year period by 2030. Full Xpert decentralization could eliminate untested samples by enabling on site testing at all facilities, reduce false positive diagnosis to 25%, and lead to 220 additional treatment initiations, 140 fewer unnecessary treatments, and 180 lives saved per million relative to baseline from 2023-2030. Decentralizing Xpert testing offers significant benefits, improving diagnostic accuracy, reducing untested samples, and enhancing TB treatment outcomes - but wide-scale implementation is required to realize full benefits at a country level.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

